Exploring the heterogeneity of the vaccine-elicited T cell response by scRNAseq

NIH RePORTER · NIH · R21 · $233,250 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY Clinically relevant cellular responses to either experimental or FDA approved vaccine adjuvant formulations have been difficult to generate and/or detect. Given the robust cellular responses against infectious challenge, a reasonable assumption is that subunit vaccine formulations will better achieve cellular responses by following the established rules governing the response to infections. However, we have shown that subunit vaccine- elicited T cell responses are dependent on numerous factors (cytokines, transcription factors, metabolic pathways) which are irrelevant, or even restrictive, to the T cell response to infectious challenge. More recent preliminary scRNAseq results suggest that subunit vaccination generates an entirely unique population of T cells unobserved in response to infectious challenge, capable of rapid, robust, and enduring memory formation. The present proposal will examine the heterogeneity of both vaccine-elicited and infection-elicited T cell responses over time, to what degree this heterogeneity overlaps with each other, and whether or not specific T cell populations are predictive of an adjuvants' capacity for eliciting T cells and therefore be useful in stratifying adjuvants along the axis of protective CD8+ T cell memory generation.

Key facts

NIH application ID
10218805
Project number
1R21AI156456-01A1
Recipient
UNIVERSITY OF COLORADO DENVER
Principal Investigator
Ross M Kedl
Activity code
R21
Funding institute
NIH
Fiscal year
2021
Award amount
$233,250
Award type
1
Project period
2021-01-28 → 2022-12-31